Clinical Trials Logo

Tumor-induced Osteomalacia (TIO) clinical trials

View clinical trials related to Tumor-induced Osteomalacia (TIO).

Filter by:
  • None
  • Page 1

NCT ID: NCT05357573 Active, not recruiting - Clinical trials for Tumor-Induced Osteomalacia (TIO)

Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO

Start date: September 7, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the safety, pharmacokinetics and efficacy of KRN23 in adult Chinese patients with TIO

NCT ID: NCT04783428 Active, not recruiting - Clinical trials for Tumor-induced Osteomalacia (TIO)

Tumor-induced Osteomalacia Disease Monitoring Program

Start date: January 31, 2022
Phase:
Study type: Observational

The objectives of this observational study are to assess the long-term safety and long-term effectiveness of burosumab in patients with TIO who are being treated with burosumab as prescribed by their physician and to monitor the course of the underlying phosphaturic mesenchymal tumor (PMT) overtime in patients with TIO irrespective of their treatment status.

NCT ID: NCT02304367 Completed - Clinical trials for Tumor Induced Osteomalacia (TIO)

Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)

Start date: March 24, 2015
Phase: Phase 2
Study type: Interventional

The primary objectives of this study are to evaluate the effect of burosumab treatment on: - Increasing serum phosphorus levels in adults with TIO or ENS-associated osteomalacia - Improvement in TIO/ENS-associated osteomalacia as determined by osteoid thickness (O.Th), osteoid surface/bone surface (OS/BS), osteoid volume/bone volume (OV/BV) and mineralization lag time (MLt).